CAS: 1303607-60-4; Sar405838
- 英文名称Sar405838
- 中文名称螺[3H-吲哚-3,3'-吡咯烷]-5'-甲酰胺,6-氯-4'-(3-氯-2-氟苯基)-2'-(2,2-二甲基丙基)-1,2-二氢-N-(反式-4-羟基环己基)-2-氧代-, (2'S,3R,4'S,5'R)-
- IUPAC名称(2'S,3R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-N-((1r,4R)-4-hydroxycyclohexyl)-2'-neopentyl-2-oxospiro[indoline-3,3'-pyrrolidine]-5'-carboxamide
- 其它别名(2'R,3R,3'S,5'S)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-5'-(2,2-Dimethylpropyl)-N-(4-Hydroxycyclohexyl)-2-Oxospiro[1H-Indole-3,4'-Pyrrolidine]-2'-Carboxamide; 3-Heptanone, 6-(Dimethylamino)-4,4-Diphenyl-, (6R)- (9Ci); A
- CAS编号1303607-60-4
- MFCD编号:MFCD28976052
- FDA UNII编号:8570LZ3RCA
- 分子式:C29H34Cl2FN3O3分子量:562.51
- 产品CID: 461468
- 同类组份化合物CAS1303607-07-91303607-60-4
- 产品分类生物化工 → 抑制剂 → 细胞凋亡(Apoptosis)
物理性质
- 沸点732.1±60.0 °C(预测)
- 密度1.36±0.1 g/cm3(预测)
- pKa:12.03±0.70(预测)
- PSA:90.46
- LogP:6.1602
- 溶解性≥17.2 mg/mL In DMSO
- 外观形态白色至类白色粉末
- 储存条件储存在 -20°C
- 产品应用该化合物是口服生物可获MDM2对抗物,基体0.88纳米,目前处于第一阶段临床试验阶段;有效抑制SJSA-1,RS4,11,LNCAP和HCT-116肿瘤细胞的扩散,IC50值分别为0.092微克/M,0.089微克/米,0.27微克/M和0.20微克/微M;显示对P53-MODANT或P53-KNOCKOUT肿瘤细胞线的高度选择性,包括SAOS-2,PC-3,SW3,SV620和HCT-116(P53-7---),其IC50值大于10微克-M,>10微M, >10微米/M和>20微M的细胞;在硫化中,SJAS-1的肿瘤模型中以剂量为主抑制肿瘤生长,RS4;11 急性淋染性乳腺血癌,10-116的口腔癌,HCT-116.
MSDS等安全信息
上下游产品
(3S,3'S,4'R,6'R,8'S,8A'R)-6-Chloro-8'-(3-Chloro-2-Fluorophenyl)-6'-Neopentyl-3',4'-Diphenyl-3',4',8',8A'-Tetrahydrospiro[indoline-3,7'-Pyrrolo[2,1-C][1,4]Oxazine]-1',2(6'H)-Dione 897365-81-0合成工艺路线路线简述
📜3-氯-2-氟苯甲醛置于吡啶,Ammonium Cerium (Iv) Nitrate体系中,用 甲醇,二氯甲烷,水,丙酮,甲苯,乙腈 用作溶剂,化学反应 72.0H,反应生成(2'S,3'R,4'S,5'R)-6-Chloro-4'-(3-Chloro-2-Fluoro-Phenyl)-2'-(2,2-Dimethyl-Propyl)-2-Oxo-1,2-Dihydro-Spiro[indole-3,3'-Pyrrolidine]-5'-Carboxylicacid(Trans-4-Hydroxy-Cyclohexyl)-Amidecas号:1303607-60-4
参考文献:Spiro-Oxindole Mdm2 Antagonists
标题:Spiro-Oxindole Mdm2 Antagonists
摘要:本文提供了关于药物化学领域的化合物,组合物和方法.这里提供的化合物和组合物涉及螺环氧吲哚,其作为p53和mdm2相互作用的拮抗剂,并且它们作为治疗癌症和其他疾病的药物的用途.
海关参考信息
- 2902600000-乙苯
2902700000-异丙基苯
2903919090-氯苯
2905122000-异丙醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2023037284-A9
优先权日:2018-11-30
标题:Combination therapy of peptidomimetic macrocycles
发明人：GUERLAVAIS VINCENT; ANNIS DAVID ALLEN
权利人:AILERON THERAPEUTICS INC
摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.
专利号:US-2018371021-A1
优先权日:2017-05-11
标 题 :Peptidomimetic macrocycles and uses thereof
发明人：AIVADO MANUEL; GUERLAVAIS VINCENT; OLSON KAREN
权利人:AILERON THERAPEUTICS INC
摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: de Weger VA, de Jonge M, Langenberg MHG, Schellens JHM, Lolkema M, Varga A, Demers B, Thomas K, Hsu K, Tuffal G, Goodstal S, Macé S, Deutsch E. A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. Br J Cancer. 2019 Feb;120(3):286-293. doi: 10.1038/s41416-018-0355-8. Epub 2018 Dec 26. doi: 10.1016/j.ejmech.2018.09.044. Epub 2018 Sep 18. Review. doi: 10.1158/1535-7163.MCT-17-0600. Epub 2018 Jul 3.
4: Krasavin M, Gureyev MA, Dar'in D, Bakulina O, Chizhova M, Lepikhina A, Novikova D, Grigoreva T, Ivanov G, Zhumagalieva A, Garabadzhiu AV, Tribulovich VG. Design, in silico prioritization and biological profiling of apoptosis-inducing lactams amenable by the Castagnoli-Cushman reaction. Bioorg Med Chem. 2018 May 15;26(9):2651-2673. doi: 10.1016/j.bmc.2018.04.036. Epub 2018 Apr 18. doi: 10.1038/onc.2017.258. Epub 2017 Aug 7.
6: Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5. Review.
合成参考文献
参考文献:10.1021/acs.jmedchem.0c00829
摘要:Talele TT. Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon. J Med Chem. 2020 Nov 25;63(22):13291–315. doi: 10.1021/acs.jmedchem.0c00829.
摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
📝 需求与反馈
尽可能描述清楚需求与问题信息
